With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer. Tremelimumab has ...
Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...
Reuters Antitrust Correspondent Jody Godoy interviews FTC Bureau of Competition Director Daniel Guarnera at Reuters Pharma USA this week in Philadelphia. With patent cliffs approaching and plenty of ...
February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the ...
First developed in the 1960s, they are supported by extensive clinical evidence and recommended by leading professional ...
It’s been an exciting time recently for Boehringer Ingelheim oncology as the company recently received FDA approval for Hernexeos (zongertinib) just 44 days after submission under the FDA’s new ...
Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity, a rare condition in which damage to or a malfunction of the hypothalamus leads to excessive weight gain ...
Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.
Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal ...
After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results